Phase II study alternating mFOLFOX 6 and FOLFIRI (FIREFOX) plus bevacizumab (bev) regimen in first-line treatment of advanced colorectal cancer in Japanese patients (KSCC 0801).
Yutaka Ogata
No relevant relationships to disclose
Yoshito Akagi
No relevant relationships to disclose
Yoshihiro Kakeji
Honoraria - Chugai Pharma
Yasunori Emi
No relevant relationships to disclose
Eiji Oki
No relevant relationships to disclose
Hiroshi Saeki
No relevant relationships to disclose
Tetsuo Touyama
No relevant relationships to disclose
Hironori Samura
No relevant relationships to disclose
Hideo Baba
No relevant relationships to disclose
Shoji Natsugoe
No relevant relationships to disclose
Kazuo Shirouzu
No relevant relationships to disclose
Shoji Tokunaga
No relevant relationships to disclose
Yoshihiko Maehara
Research Funding - Chugai Pharma; Yakult